

# The role of valvular bronchoblocation in the complex management of pulmonary tuberculosis

**Prof. Kakha Vacharadze**  
**MD Teona Mskhaladze**

**National Center for Tuberculosis and Lung Diseases**  
**Tbilisi State Medical University**



2024



გუბერკულოზისა და ფილგვის  
ღააპაღეგათა ეროვნული ცენტრი



# Interventional pulmonology




Interventional pulmonology is an effective method for managing severe and uncontrolled diseases of the respiratory system when medical treatment is ineffective and surgical treatment is contraindicated.



One of the areas of interventional pulmonology is valvular bronchoblocation, which has been approved by the FDA for lung volume reduction in patients with severe emphysema and COPD.




In recent years, valvular bronchoblocation has been used in both Asian and European countries for destructive forms of pulmonary tuberculosis.






# Valvular bronchoblocation in the complex management of pulmonary tuberculosis



As a result of the successful use of valve bronchial occlusion in Georgia, this method was included in the new national tuberculosis management guidelines in 2021 and funded by a state program as a separate treatment component.




# Method of Valvular Bronchoblocation









# Endobronchial Valves



Zephyr® ენდობრონქიალური სარქველი




ქოლგის ფორმის  
Spiration IBV® სარქველი.



Emphasys EBV




Medlung-ის სარქველი



Hollow cylinder

Collapsible petal-like valve



Bridge that holds the valve

Radial petals

Internal valve opening

**Design of the endobronchial valve**

343

1

12:33:24

BB  
David Tchkonja  
NCTLD




544  
1

11:58:42

Extraction at 38  
David Tchkonta  
NCTLD



# Indications and Contraindications for the Valvular Bronchoblocation



## Indications

1. Bleeding from the respiratory tract
2. Emphysema
3. Pneumothorax
4. Broncho-pleural fistula


## Contraindications

1. Purulent endobronchitis
2. Bronchiectasis
3. Acute cardiovascular failure
4. Malignant tumor






# Collapse Therapy



## Thoracoplasty



## Pneumoperitoneum




## Bronchoblocation






# Statistics of pulmonary tuberculosis in Georgia 2023



- A total of 1,448 TB cases were reported;
- 1144 A new case and 304 Relapse;
- 8.9% of new cases and 24% of previously treated cases were resistant tuberculosis. The effectiveness of the treatment of resistant forms does not exceed 75%.
- Mortality was observed: 4% of sensitive patients; 6% of resistant patients.





## Valvular Bronchoblocation Research conducted at the National Center for Tuberculosis and Lung Diseases



- Pulmonary tuberculosis is a significant public health problem both in the world and in Georgia. Despite the inclusion of new drugs in the treatment regimens for resistant tuberculosis, resistance to these drugs has already been observed;
- The results of the treatment of pulmonary tuberculosis are still unexplored and remain an important problem for WHO;
- Long-term studies have shown that mortality after transmission of pulmonary tuberculosis is much higher than in the general population;






# Study Patients






# Diagnostic Methods








# Study Results




## Results of X-ray examination

### Infiltration



2 vs. 1 - Chi2- test = 46.44; p<0.001  
 2 vs. 1 - Chi2- test = 120.04; p<0.001


### cavitation




2 vs. 1 - Chi2- test = 21.50; p<0.001  
 2 vs. 1 - Chi2- test = 10.57; p<0.001  
 study vs. control - Chi2-test=18.00, p<0.001  
 3 vs. ეტაპი 2- Chi2- test = 4.10; p=0.043  
 3 vs. ეტაპი 2 - Chi2- test = 4.65; p=0.031  
 study vs. control - Chi2-test=19.94, p<0.001



# Study Results



## Dynamics of the results of bacterioscopic examination of sputum by stages of the study in the main and control groups



44.1±23.2 day

63.3±25.2 day

Stage 2 vs. Stage 1 - Chi2- test = 5.61; p=0.018

Stage 3 vs. Stage 2 - Chi2- test = 2.46; p=0.117

Stage 4 vs. Stage 3 - Chi2- test = 0.21; p=0.650


**Stage 2 vs. Stage 1 - Chi2- test = 12.73; p<0.001**

**Stage 3 vs. Stage 2 - Chi2- test = 8.74; p=0.008**


**Stage 4 vs. Stage 3 - Chi2- test = 21.65; p<0.001**



# Study Results



## Dynamics of sputum cultural research results according to research stages in research and control groups



2 vs. 1 - Chi2- test = 8.89; p=0.002

3 vs. 2 - Chi2- test = 3.46; p=0.021

4 vs. 3 - Chi2- test = 0.61; p=0.443


2 vs. 1 - Chi2- test = 16.81; p<0.001

3 vs. 2 - Chi2- test = 11.53; p<0.001

4 vs. 3 - Chi2- test = 7.53; p=0.003



# Study Results



The treatment outcomes in the study and control groups



#	Treatment outcomes	Study group (n=65)	Control group (n=125)
1	Cure	57 (87.7%)	107 (85.6%)
2	Death	3 (4.6%)	9 (7.2%)
3	Without result	2 (3.1%)	0 (0.0%)
4	Unknown	3 (4.6%)	9 (7.2%)

Cure OR = 0.72; 95%CI – 0.37-1.39



# Study Results

number of patients




OR=3.77, 95%CI – 2.00-7.13, p<0.001






# Study Results


## Comparison of treatment effects during bleeding



### Study Subgroup





### Control Subgroup






# Study Results

## Bleeding Bronchus






# Study Results




## Time to achieve hemostasis




$t=9.10; p<0.001$



# Study Results




## Terms of hospitalization





# Study Results



The treatment outcomes in the study and control subgroups

#	Treatment outcomes	Study group (n=43)	Control group (n=44)
1	Cure	39 (90.7%)	25 (56.8%)
2	Death	2 (4.7%)	9 (20.5%)
3	Surgery	2 (4.7%)	10 (22.7%)

Cure - OR = 4.34; 95%CI – 1.72-10.96; p=0.002





Death- OR =5.27; 95%CI – 1.07-26.04; p=0.041

Surgery- OR = 7.41; 95%CI – 2.25-24.34; p=0.001





# Case N1






Chest CT scan after treatment








# Case N1



Chest CT scan 2.5 years after treatment



## Case N2






Chest CT scan before valvular broncho blocation






# Case N2



Chest CT scan 6 month after treatment



# CONCLUSIONS




- Based on observation and statistical analysis of the dynamics of radiological data, a significant reduction in cavitary changes has been identified in the main group.
- On the basis of observation and statistical analysis of sputum bacterioscopic and cultural examinations, a significant decrease in contamination and conversion of culture has been demonstrated.
- From the parameters of general blood analysis, liver enzymes, bilirubin and kidney function indicators were not significantly changed in the study and control groups at the same stages of the study.
- The rate of post-intervention surgical intervention in the bronchoblockage subgroup of patients with ongoing tuberculosis and bleeding complications was significantly lower compared to the conservative therapy subgroup. There was also significantly less lethal outcome compared to the control group.
- Based on the dynamics of the above-mentioned radiological, bacterioscopic and cultural studies, valve bronchoblockage leads to the prevention of the consequences of tuberculosis.






# PRACTICAL RECCOMENDATIONS



- Valvular bronchoblocation is considered as a less invasive and safer therapeutic method in the management of tuberculosis. Therefore, it's. widespread use is recommended in TB patients.
- The use of the valvular bronchoblocation is recommended to prepare patients for planned surgical interventions.
- In case of bleeding of any intensity, if conservative treatment is ineffective, valvular bronchoblocation is recommended.



# The role of valvular bronchoblocation in the complex management of pulmonary tuberculosis



**Thank you  
for your attention...**